Entropy Neurodynamics Issues Shares in Lieu of Director Fees Under Secondary Trading Provisions

The latest announcement is out from Tryptamine Therapeutics ( (AU:ENP) ).

Entropy Neurodynamics has issued 1,931,012 fully paid ordinary shares to directors in lieu of cash fees, following shareholder approval at its November 2025 annual general meeting, and has lodged a corresponding Appendix 2A with the ASX. The company confirmed that the share issue was conducted without a prospectus under the Corporations Act’s secondary trading provisions, that it remains compliant with its financial reporting and continuous disclosure obligations, and that there is no excluded information, signaling routine governance and compensation management rather than a change in operating outlook.

The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited (ASX: ENP) is an Australia-based company listed on the ASX, operating in the neurotechnology and therapeutics sector, though this announcement provides no additional detail on its specific products, services or target markets.

Average Trading Volume: 2,158,840

Technical Sentiment Signal: Sell

Current Market Cap: A$51.5M

For an in-depth examination of ENP stock, go to TipRanks’ Overview page.